Insights

Gathering insights about SAVA…

Similar companies to SAVA

Philips
$10B

SAVA Tech Stack

SAVA uses 8 technology products and services including GitHub Actions, React, PHP, and more. Explore SAVA's tech stack below.

GitHub Actions
Devops
React
Javascript Frameworks
PHP
Programming Languages
Python
Programming Languages
Google
Search Engines
Onsen UI
Software Development
Bootstrap
UI Frameworks
LabVIEW
Visualisation Software

Media & News

Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)
Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Cassava Sciences (NASDAQ: SAVA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Institutional and Insider Ownership 44.3% of Carisma
Nov 05, 2025 | www.defenseworld.net
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders. If you currently own Cassava stock and acquired shares on or before September 14, 2020, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to l.
Oct 22, 2025 | www.businesswire.com
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board).
Oct 22, 2025 | www.globenewswire.com
Cassava Reports Q2 2025 Financials Results and Provides Business Update
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2025 and provided a business update.
Aug 14, 2025 | www.globenewswire.com
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, Cassava's investigational candidate for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy.
Aug 07, 2025 | www.globenewswire.com
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, today reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex (TSC)-related epilepsy.
Aug 04, 2025 | www.globenewswire.com
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that the Company presented a poster at the TSC International Research Conference (TSC 2025) held June 26-28, 2025 in Bethesda, MD. The poster, available on the Company website via this link, detailed two important observations that support Cassava's plan to initiate human clinical studies in H1 2026 to evaluate simufilam as a treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy: Preclinical proof-of-concept: Treatment with simufilam alleviated neuronal abnormalities and reduced seizure frequency by 60% compared to vehicle in a mouse model of focal onset seizures.
Jun 30, 2025 | www.globenewswire.com

SAVA's Email Address Formats

SAVA uses at least 2 format(s):

SAVA Email Formats	Example	Percentage
First@caura.me	John@caura.me	94%
First.L@caura.me	John.D@caura.me	6%
First@sava.health	John@sava.health	100%

Frequently Asked Questions

Where is SAVA's headquarters located?

SAVA's main headquarters is located at 117 Charterhouse Street, London, England EC1M 6AA, GB. The company has employees across 5 continents, including EuropeAsiaNorth America.

What is SAVA's stock symbol?

SAVA is a publicly traded company; the company's stock symbol is SAVA.

What is SAVA's official website and social media links?

SAVA's official website is sava.health and has social profiles on LinkedIn Crunchbase.

What is SAVA's SIC code NAICS code?

SAVA's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does SAVA have currently?

As of October 2025, SAVA has approximately 101 employees across 5 continents, including EuropeAsiaNorth America. Key team members include Vice President Of Manufacturing: C. D.Head Of Operations: O. S.Head Of Systems & Software: J. P. M. A.. Explore SAVA's employee directory with LeadIQ.

What industry does SAVA belong to?

SAVA operates in the Biotechnology Research industry.

What technology does SAVA use?

SAVA's tech stack includes GitHub ActionsReactPHPPythonGoogleOnsen UIBootstrapLabVIEW.

What is SAVA's email format?

SAVA's email format typically follows the pattern of First@caura.me. Find more SAVA email formats with LeadIQ.

How much funding has SAVA raised to date?

As of October 2025, SAVA has raised $19M in funding. The last funding round occurred on Jul 30, 2025 for $19M.

When was SAVA founded?

SAVA was founded in 2016.

SAVA

Q: What is SAVA's official website and social media links?

SAVA's official website is sava.health. SAVA has social profiles on LinkedIn.

Q: How many employees does SAVA have currently?

SAVA has approximately 101 employees.

Q: What technology does SAVA use?

SAVA's tech stack includes React, Webpack, SOLIDWORKS PDM, MATLAB, reCAPTCHA.

Biotechnology ResearchUnited Kingdom51-200 Employees

All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.

Company Overview

Headquarters: 117 Charterhouse Street, London, England EC1M 6AA, GB
Website: sava.health
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: SAVA
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2016
Employees: 51-200

Media & News

Funding & Financials

$19M
SAVA has raised a total of $19M of funding over 6 rounds. Their latest funding round was raised on Jul 30, 2025 in the amount of $19M.
$1M$10M
SAVA's revenue is estimated to be in the range of $1M$10M

Funding & Financials

$19M
SAVA has raised a total of $19M of funding over 6 rounds. Their latest funding round was raised on Jul 30, 2025 in the amount of $19M.
$1M$10M
SAVA's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to SAVA

Philips

SAVA Tech Stack

Media & News

Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

SAVA's Email Address Formats

Frequently Asked Questions

Where is SAVA's headquarters located?

What is SAVA's stock symbol?

What is SAVA's official website and social media links?

What is SAVA's SIC code NAICS code?

How many employees does SAVA have currently?

What industry does SAVA belong to?

What technology does SAVA use?

What is SAVA's email format?

How much funding has SAVA raised to date?

When was SAVA founded?

SAVA

Company Overview

Media & News

Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?